Expression of 1A6 gene and its correlation with intestinal gastric carcinoma

Yi-Qiang Liu, Hong Zhao, Tao Ning, Yang Ke, Ji-You Li

Abstract

AIM: To investigate the expression of 1A6 gene in the lesions during the development of intestinal gastric carcinoma.

METHODS: One hundred and thirty-six cases of intestinal metaplasia (IM) from surgical resections and biopsies were classified by mucus staining. Expression of 1A6 in all cases was detected using immunohistochemical S-P method.

RESULTS: The positive rates of 1A6 in normal and superficial gastritis (SG), severe atrophic gastritis (SAG), type I, II, III IM, dysplasia (Dys) and intestinal gastric carcinoma (IGC) were 12.2%, 16.7%, 7.1%, 22.6%, 47.8%, 46.9% and 60.8%, respectively. A significant difference among type III IM and SG, SAG, type I and II IM was found (P<0.01), the difference between type III and Dys, IGC being not significant.

CONCLUSION: As a new tumor-related gene, expression of 1A6 may be an effective parameter to predict the malignant transformation of precancerous lesion to gastric carcinoma.

Liu YQ, Zhao H, Ning T, Ke Y, Li JY. Expression of 1A6 gene and its correlation with intestinal gastric carcinoma. World J Gastroenterol 2003; 9(2): 238-241.

http://www.wjgnet.com/1007-9327/9/238.htm

INTRODUCTION

Gastric cancer is a major health problem in the world[1-3]. Clinical statistics have shown that 50% of gastric cancer in China are intestinal type adenocarcinoma[4]. The phenotypic events in intestinal gastric carcinoma have been well recognized as normal gastric mucosa, chronic superficial gastritis, severe atrophic gastritis, intestinal metaplasia, dysplasia, intramucosal (“early”) carcinoma and invasive carcinoma[5,6]. A considerable number of oncogenes and antioncogenes involved in this process have been described, such as c-met, p53, c-erbB-2, APC, PCNA, p16, akt etc[7-12]. Unfortunately, they are not gastric carcinoma-specific. No significant progress has been made in the existing studies concerning special genotypic abnormalities in the premalignant lesions of gastric carcinoma. 1A6 is a novel tumor-related gene. In this study, immunohistochemistry was used to detect the expression of 1A6 protein in IGC, its premalignant lesions and normal counterparts.

MATERIALS AND METHODS

Patients and specimens
Paraffin-embedded archival materials from surgical resections and biopsies were performed during 1998 to 2001 in our department. There were 92 cases of gastric carcinoma (62 men and 30 women; aged 29-81 years), among them 51 cases were IGC, and 41 cases were diffuse gastric carcinoma (DGC). The criterion for classifying gastric carcinoma was derived largely from the observations of Lauren[13]. The 23 sarcoma patients consisted of 15 men and 8 women, their ages ranged from 20 to 81 years. The histopathologic types included malignant fibrohistiocytoma, leiomysarcoma, liposarcoma, fibrosarcoma, malignant stromal tumor and malignant peripheral nerve sheath tumor. According to the updated Sydney system[14] and the Padova International Classification for Gastric Dysplasia[15], 198 cases from biopsy (109 men and 89 women; age ranged from 27-82 years) were divided into four groups: normal mucosal and chronic superficial gastritis (41 cases), severe atrophic gastritis without IM (24 cases), IM (136 cases) and dysplasia (32 cases).

Mucin histochemistry
We performed mucin histochemical studies on 136 cases of IM to classify them using HID/AB/PAS staining described previously[16-19]. The variants fell into three main groups: type I (complete type) shows features of mature small intestinal epithelium, type II (incomplete small intestinal type) had features of both gastric and small intestinal epithelia, whereas type III (incomplete colonic type) has characteristics of large intestines. Neutral mucins appeared magenta in color (PAS positive), sialomucins, blue color (AB positive) and sulphomucins brown (HID positive), respectively. The criteria for classifying IM are given in Table 1.

Table 1 Classification of IM

| Type    | PAS | AB | HID |
|---------|-----|----|-----|
| Type I  | -   | +  | -   |
| Type II | +   | +  | -   |
| Type III| +   | +  | +   |

Immunohistochemical staining
To investigate the expression of 1A6 protein, we adopted the standard S-P immunohistochemical method[20]. The 1A6 monoclonal antibody was provided by the Laboratory of Genetics, Beijing Institute of Cancer Research, its dilution was 1:500. The SP kit was provided by Beijing Zhongshan Biotechnology Company. All the slides were treated with PBS and were microwaved for antigen retrieval. 1A6 protein was located in nuclei. Only the samples with more than 10% cells stained could be considered positive.
**Statistical analysis**

The difference of 1A6 protein expression among different lesions was analyzed by χ² square test. A P value of less than 0.05 was considered statistically significantly.

**RESULTS**

**Expression of 1A6 protein in gastric carcinoma and sarcoma**

The positive expression rate of 1A6 protein in all types of gastric carcinoma was 48.9 % (45/92). In contrast, 1A6 protein was negative in all cases of sarcoma (Figure 1). In comparison of IGC and DGC, there was significant difference (P<0.01). In IGC, the positive rate was 60.8 % (31/51), whereas the positive rate in DGC was 34.1 % (14/41). Most positive cells showed a nuclear and plasmatic staining (Figure 2).

**Expression of 1A6 protein in intestinal metaplasia**

According to the mucin histochemistry, there were 14 cases of type I IM, 53 cases of type II IM and 69 cases of type III IM. The expression of 1A6 protein in all kinds of IM is shown in Table 2 (Figures 3, 4, 5). The positive rate of type III was significantly higher than that of the other two types. A nuclear and plasmatic staining was also found in most positive cases (Figure 6).

| Type   | n  | 1A6(+) (%) | 1A6(-) (%) |
|--------|----|------------|------------|
| Type I | 14 | 1 (7.1)    | 13 (92.9)  |
| Type II| 53 | 12 (22.6)  | 41 (77.4)  |
| Type III| 69 | 33 (47.8)  | 39 (52.2)* |

* P <0.005 (χ²=7.965, 8.167), vs type I IM, type II IM, respectively.
Expression of 1A6 protein in normal mucosa and SG, SAG, type III IM, Dys and IGC

As the stomach mucosa changed from benign lesion to malignant tumor, the positive expression of 1A6 protein became higher and higher (Table 3). The positive rate of type III, Dys and IGC were higher than SG and SAG, the difference being statistically significant (P<0.01). On the contrary, there were no significant differences among type III IM, Dys and IGC.

Table 3 Expression of 1A6 in different lesions of stomach

|           | n   | 1A6 + (%�) |
|-----------|-----|------------|
| Normal mucosa and SG | 41  | 5(12.2)    |
| SAG       | 24  | 4(16.7)    |
| Type III IM | 69  | 33(47.8)※ |
| Dys       | 32  | 15(46.9)※ |
| IGC       | 51  | 31(60.8)※ |

・P < 0.01 (χ^2=7.494), vs normal mucosa and SG; ※P < 0.01 (χ^2=10.067), vs normal mucosa and SG; □P < 0.01 (χ^2=16.298), vs normal mucosa and SG.

DISCUSSION

Recently, many investigations concerning intestinal metaplasia of stomach have been made in different aspects such as epidemiology, pathology and molecular biology.[21-23] Although there were controversies about the phenotypic and genotypic events of IM, it has been widely accepted that the incomplete colonic type IM plays an important role in the histogenesis of gastric carcinoma and it is considered as the premalignant lesion of intestinal gastric carcinoma.[21-24-28]

Gene 1A6 is a novel tumor-associated gene cloned from malignant cell line MC, which is an MNNG-treated human fetal gastric epithelial cell line. 1A6 is located in chromosome 12q23.2-23.3. Its cDNA is about 3kb. There are HEAT motif and nucleus-located sequence in 1A6 protein by molecular sequence analysis. 1A6 protein nucleus localization was further confirmed by immunofluorescence and immuno-electron microscopy. It was found in nucleole and heterochromatin. It suggested that 1A6 protein could interact with other proteins and may play a role as a nuclear transcription factor. Immunohistochemical studies in different tumors indicated that 1A6 was expressed not only in gastric carcinoma, but also in esophageal and breast cancers.[29-31]

As mentioned above, type III IM is thought to be the premalignant lesion of gastric carcinoma.[29-30] In our study, the positive expression rate of 1A6 protein was very high in type III IM, which suggests that the overexpression of gene 1A6 maybe an early event in gastric malignant transformation. It can be an important index for predicting the carcinogenesis of stomach. How 1A6 protein functions in transformation of the intestinal metaplasia tissue into malignant tumor and the interaction between other oncogenes and antioncogenes need further investigation and the work is undergoing.

In this study, it was found that although the positive expression rate of 1A6 protein in DGC was much lower than that of IGC, one third of them were positive too. These results indicate that as gastric carcinoma, IGC and DGC may share some common characteristics, although their biological characteristics and etiological molecular mechanism are very different. In 23 cases of sarcoma, the positive rate was 0 %, it is no doubt that 1A6 protein is epithelial-tumor-specific.

In this study, many positive cells showed both nuclear and plasmatic staining. There are three possibilities: (1) The synthesis of nuclear proteins takes place in cell plasma, and then transmit into the nucleus, the plasmatic positivity might reflect the newly synthesized 1A6 protein. (2) Non-specific binding of 1A6 Ab with other plasmatic proteins. (3) Non-specific secondary Ab binding with the proteins in the plasma.

In conclusion, 1A6 is a new tumor-related gene, its expression may play an important role in the early stage of gastric carcinogenesis. The detection of 1A6 protein in the premalignant lesions of intestinal gastric carcinoma may be a very valuable index to predict the malignant transformation of these lesions.

REFERENCES

1. Nie YZ, HeFT, Li ZK, Wu KC, Cao YX, Chen BJ, Fan DM. Identification of tumor associated single-chain Fv by screening and antibody phage library using tumor cells. World J Gastroenterol 2002; 8: 613-623
2. Deng DJ. Progress of gastric cancer etiology: N-nitrosamides in the 1990s. World J Gastroenterol 2000; 6: 613-618
3. Chen GY, Wang DR. The expression and clinical significance of CD44v in human gastric cancers. World J Gastroenterol 2000; 6: 125-127
4. Sij M, Zhou W, Wu JG, Cao Q, Xiang Z, Jiang L, Lu W, Huang H. Establishment of an animal model of chronic atrophic gastritis and a study on the factors inducing atrophy. Chin Med J 2003; 114: 1323-1329
5. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988; 48: 3554-3560
6. Correa P. Human gastric carcinogenesis: A multistep and multifactorial process-First American cancer society award lecture on cancer epidemiology and prevention. Cancer Res 1992; 52: 6735-6740
7. Correa P, Shiao YH. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 1994; 54: 1941s-1943s
8. Tahara E. Molecular biology of gastric cancer. World J Surg 1995; 19: 484-488
9. Wu MS, Shun CT, Lee WC, Chen CJ, Wang HP, Lee WJ, Sheu JC, Lin JT. Overexpression of p53 in different subtypes of intestinal metaplasia and gastric cancer. Br J Cancer 1998; 78: 971-973
10. Xu AG, Li SG, Liu JH, Gan AH. Function of apoptosis and expression of the proteins Bcl-2, p53 and C-myc in the development of gastric cancer. World J Gastroenterol 2001; 7: 403-406
11. Ji F, Peng QB, Zhan JB, Li YM. Study of differential polymerase chain reaction of C-erbB-2 oncogene amplification in gastric cancer. World J Gastroenterol 1999; 5: 152-155
12. He XS, Su Q, Chen ZC, He XT, Long ZF, Ling H, Zhang LR. Expression, deletion and mutation of p16 gene in human gastric cancer. World J Gastroenterol 2001; 7: 515-521
13. Lauren P. The two histologic main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at a histochinical classification. Acta Pathol M (crobol Scand 1965; 64: 31-49
14. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastric foci in Sydney System. Am J Surg Pathol 1996; 20: 1161-1181
15. Rugge M, Correa P, Dixon MF, Hattori T, Leandro G, Lewin K, Diddell RH, Sipponen P, Watanabe H. Gastric dysplasia: the Padova International Classification. Am J Surg Pathol 2000; 24: 167-176
16. Jass JR. Role of intestinal metaplasia in the histogenesis of gastric carcinoma. J Clin Pathol 1993; 33: 803-810
17. Xing W, Li XL, Wang YP, Zhang SM, Zhong HC, Wu DY, Zhang YC. Relationship between phenotypes of cell-function differentiation and pathobiological behavior of gastric carcinomas. World J Gastroenterol 2001; 7: 53-59
18. Byrne JP, Bhatnagar S, Hamid B, Armstrong GR, Attwood SE. Comparative study of intestinal metaplasia and mucin staining at the cardia and esophagogastric junction in 225 symptomatic patients presenting for diagnostic open-access gastroscopy. Am J Gastroenterol 1999; 94: 98-103
19. Shihoul R, Marcon P, Okada Y, Cutz E, Forstner G. The pathogenesis of duodenal gastric metamorphosis: the role of local goblet cell transformation. Gut 2000; 46: 632-638
20. Taylor CR, Kledzik G. Immunohistologic techniques in surgical pathology: A spectrum of "new" special stains. Hum Pathol 1981;
12. Stemmermann GN. Intestinal metaplasia of the stomach: a status report. Cancer 1994; 74: 556-564
21. Yao YL, Xu B, Song YG, Zhang WD. Overexpression of cyclin E in Mongolian gerbil with Helicobacter pylori-induced gastric precancerosis. World J Gastroenterol 2002; 8: 60-63
23. Stemmermann GN, Nomura AM, Kolonel LN, Goodman MT, Wilkens LR. Gastric carcinoma: pathology findings in a multiethnic population. Cancer 2002; 95: 744-750
24. Sipponen P. Gastric cancer: pathogenesis, risks, and prevention. J Gastroenterol 2002; 37 (Suppl): 39-44
25. Leung WK, Yu L, Chan FK, To KF, Chan MW, Ebert MP, Ng EK, Chung SC, Malfertheiner P, Sung JJ. Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinoma, intestinal metaplasia, and non-neoplastic gastric tissues. J Pathol 2002; 197: 582-588
26. Leung WK, Sung JJ. Intestinal metaplasia and gastric carcinogenesis. Aliment Pharmacol Ther 2002; 16: 1209-1216
27. Takahashi H, Endo T, Yamashita K, Arimura Y, Yamamoto H, Sasaki S, Itoh F, Hirata K, Imamura A, Kondo M, Sato T, Imai K. Mucin phenotype and microsatellite instability in early multiple gastric cancers. Int J Cancer 2002; 100: 419-424
28. Dixon MF. Prospects for intervention in gastric carcinogenesis: reversibility of gastric atrophy and intestinal metaplasia. Gut 2001; 49: 2-4
29. Zhao H, Hagiwara K, Mcmenamin M, Ning T, Zheng SH, Harris CC, Ke Y. Function study of a novel tumor-related gene 1A6. Poster, AACR 91st annual meeting
30. Groves MR, Barford D. Topological characteristics of helical proteins. Curr Opin Struct Biol 1999; 9: 383-389
31. Murzin AG, Patty L. Sequence and topology: from sequence to structure to function. Curr Opin Struct Biol 1999; 9: 359-363
32. Pali D. Epidemiology of gastric cancer: an evaluation of available evidence. J Gastroenterol 2000; 35 (Suppl 12): 84-89
33. El-Zimaity HM, Ota H, Graham DY, Akamatsu T, Katsuyama T. Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer 2002; 94: 1428-1436
34. Silva E, Teixeira A, David L, Carneiro F, Reis CA, Sobrinho-Simoes M, Sobrinho-Simoes J. Mucins as key molecules for the classification of intestinal metaplasia of the stomach. Virchows Arch 2002; 440: 311-317
35. van Rees BP, Saukkonen K, Ristimaki A, Polkowski W, Tytgat GN, Drillenburg P, Offerhaus GJ. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol 2002; 196: 171-179

Edited by MajY